Understanding the Potential of Innovation in OSA Management Originally published on the National Sleep Foundation website as part of Sleep Awareness Week 2023. As part of Sleep Awareness Week®, we welcome the contributions and perspectives of our sponsors....
CAMBRIDGE, Mass. January 25, 2023 – Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea (OSA) and related disorders, including its lead oral treatment candidate AD109,...
– Phase 3 Trials Expected to Begin Enrollment in Second Quarter of 2023, Subject to Discussions with the FDA CAMBRIDGE, Mass. January 3, 2023 – Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment...
CAMBRIDGE, Mass. November 8, 2022 – Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies to address obstructive sleep apnea (OSA) and related disorders, including its lead candidate AD109, today announced that management...
